BHVN
HealthcareBiohaven Ltd.
$9.93
$-0.91 (-8.39%)
Jan 5, 2026
Price History (1Y)
Analysis
Biohaven Ltd. is a biotechnology company within the healthcare sector, with a market capitalization of $1.32 billion and approximately 256 employees. The company's financial health is marked by negative profitability metrics, including gross margin, operating margin, and profit margin all being 0.0%. Additionally, the net income and EBITDA are both significant losses, at -$780 million and -$772 million, respectively. The free cash flow is also a loss of $414 million. However, the company has a notable cash balance of $260 million and debt of $314 million, resulting in a current ratio of 2.86. The valuation context for Biohaven Ltd. presents a mixed picture, with a negative forward P/E ratio of -3.44 and an EV/EBITDA of -1.56. The price to book is also notably low at -61.30.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Biohaven Ltd.
Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment of migraines and pain disorders; BHV-1510, which is in Phase ½ trial that targets advanced or metastatic epithelial tumors; and BHV-8000, a product candidate that completed Phase 1 clinical trial for the treatment of Alzheimer's and Parkinson's disease, and multiple sclerosis, as well as prevention of amyloid-related imaging abnormalities. It is also developing BHV-1300, which in Phase 1 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 1 trial for IgA nephropathy; BHV-1100, which is in Phase 1 trial for multiple myeloma patients; BHV-1600, which is in Phase 1 trial for the treatment of peripartum cardiomyopathy; BHV-1310 that is in preclinical trial for the treatment of generalized myasthenia gravis and other acute exacerbations or flares; BHV-1530, which is in preclinical trial to treat urothelial cancer; BHV-1500 that is in preclinical trial for Hodgkin's lymphoma; and BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors. The company has strategic partnerships with Merus N.V., GeneQuantum Healthcare (Suzhou) Co. Ltd., Aimed Bio, Inc., Yale University, Katholieke Universiteit Leuven, Bristol Meyers Squibb, and Hangzhou Highlightll Pharmaceutical Co. Ltd. Biohaven Ltd. was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Visit website →Key Statistics
- Market Cap
- $1.32B
- P/E Ratio
- N/A
- 52-Week High
- $44.28
- 52-Week Low
- $7.48
- Avg Volume
- 3.96M
- Beta
- 3.54
Company Info
- Industry
- Biotechnology
- Exchange
- NYQ
- Country
- United States
- Employees
- 256